Use of asenapine in clinical practice for the management of bipolar mania
Standard
Use of asenapine in clinical practice for the management of bipolar mania. / Young, Allan H; Altamura, Alfredo Carlo; González-Pinto, Ana M; Millet, Bruno; Wiedemann, Klaus.
In: J PSYCHOPHARMACOL, Vol. 27, No. 4 Suppl, 01.04.2013, p. 3-13.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Use of asenapine in clinical practice for the management of bipolar mania
AU - Young, Allan H
AU - Altamura, Alfredo Carlo
AU - González-Pinto, Ana M
AU - Millet, Bruno
AU - Wiedemann, Klaus
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comorbidity and mortality. Treatment guidelines for bipolar mania generally recommend initiating first-line therapy with a second-generation antipsychotic or mood stabiliser, either alone or in combination. Asenapine is a second-generation antipsychotic with a unique receptor binding profile, licensed for the treatment of manic episodes in adults with bipolar I disorder. 'Real-world' data are needed to complement evidence from clinical trials, in order to provide clinicians with pragmatic information regarding the likely risks and benefits of using a new agent in clinical practice. Evidence from real-world case reports demonstrates that - as in clinical trials - asenapine is effective in treating mania and mixed episodes associated with bipolar I disorder, whether used as monotherapy or in combination with a mood stabiliser. It has a rapid onset of antimanic effect and an early improvement is associated with treatment outcome. Asenapine also shows promise in controlling depressive symptoms and clinically challenging mixed states. Asenapine has a favourable tolerability profile, compared with other first-line agents, having a minimal impact on weight and metabolic parameters. Asenapine should be considered a first-line treatment option for adults with bipolar I disorder.
AB - Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comorbidity and mortality. Treatment guidelines for bipolar mania generally recommend initiating first-line therapy with a second-generation antipsychotic or mood stabiliser, either alone or in combination. Asenapine is a second-generation antipsychotic with a unique receptor binding profile, licensed for the treatment of manic episodes in adults with bipolar I disorder. 'Real-world' data are needed to complement evidence from clinical trials, in order to provide clinicians with pragmatic information regarding the likely risks and benefits of using a new agent in clinical practice. Evidence from real-world case reports demonstrates that - as in clinical trials - asenapine is effective in treating mania and mixed episodes associated with bipolar I disorder, whether used as monotherapy or in combination with a mood stabiliser. It has a rapid onset of antimanic effect and an early improvement is associated with treatment outcome. Asenapine also shows promise in controlling depressive symptoms and clinically challenging mixed states. Asenapine has a favourable tolerability profile, compared with other first-line agents, having a minimal impact on weight and metabolic parameters. Asenapine should be considered a first-line treatment option for adults with bipolar I disorder.
KW - Adult
KW - Antipsychotic Agents
KW - Bipolar Disorder
KW - Heterocyclic Compounds with 4 or More Rings
KW - Humans
KW - Male
KW - Randomized Controlled Trials as Topic
KW - Treatment Outcome
U2 - 10.1177/1359786813482534
DO - 10.1177/1359786813482534
M3 - SCORING: Journal article
C2 - 23535350
VL - 27
SP - 3
EP - 13
JO - J PSYCHOPHARMACOL
JF - J PSYCHOPHARMACOL
SN - 0269-8811
IS - 4 Suppl
ER -